- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 103/40 - Actinides
Patent holdings for IPC class A61K 103/40
Total number of patents in this class: 86
10-year publication summary
|
2
|
1
|
2
|
3
|
0
|
5
|
5
|
11
|
15
|
10
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Novartis AG | 10263 |
3 |
| Algeta ASA | 14 |
3 |
| Memorial Sloan-Kettering Cancer Center | 2038 |
3 |
| Nihon Medi-physics Co., Ltd. | 177 |
3 |
| Ariceum Therapeutics GmbH | 20 |
3 |
| Mariana Oncology Inc. | 19 |
3 |
| Ratio Therapeutics, Inc. | 21 |
3 |
| Novartis Pharma AG | 226 |
2 |
| Actinium Pharmaceuticals Inc. | 146 |
2 |
| Advanced Accelerator Applications USA, Inc. | 6 |
2 |
| Bayer AS | 36 |
2 |
| Cornell University | 3421 |
2 |
| Ecole Nationale Superieure de Chimie de Montpellier | 233 |
2 |
| Helmholtz-Zentrum Dresden-Rossendorf e.V. | 140 |
2 |
| Institut National de La Sante et de La Recherche Medicale (inserm) | 3219 |
2 |
| Institut Regional du Cancer de Montpellier | 106 |
2 |
| Janssen Biotech, Inc. | 1762 |
2 |
| Kyoto University | 2898 |
2 |
| Perseus Proteomics Inc. | 60 |
2 |
| Universite de Montpellier | 1042 |
2 |
| Other owners | 39 |